Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: VistaGen Therapeutics Inc. VTGN

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) … Continue reading

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming March Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer, Shawn Singh, … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Preclinical Data Demonstrating Differentiated Mechanism of Action of PH10 from Benzodiazepines

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced promising preclinical data for its PH10 drug candidate. The data demonstrate that the potential mechanism of action of … Continue reading

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Pipeline Holds Potential to Go Beyond Standard of Care for Anxiety, Depression

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications that go beyond the standard of care for anxiety and depression. A recent article discussing this reads, “Depression and anxiety are at the forefront … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation Alternatives to Current Standard of Care for Anxiety Disorders

American Psychiatric Association poll reveals 62% of respondents have anxiety about COVID-19Recent FDA Drug Safety Communication requires updated Boxed Warning for benzodiazepines commonly used to treat anxiety disordersVTGN is committed to developing and commercializing PH94B, a first-in-class pherine nasal spray … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation of Medicines with Potential to Treat Rising Mental Health Challenges from Depression

Mental health experts note growing concern over impact of COVID-19 on nation’s mental healthCompounding stress could have serious health, social consequencesVTGN offers new hope to those dealing with depression disorders A new survey from the American Psychological Association (“APA”) shines … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 Financial Report, Clinical Studies Update

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial numbers for its fiscal 2021 … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preparing Phase 3 Trial to Evaluate Neuroactive Nasal Spray Treatment for SAD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to begin a Phase 3 clinical … Continue reading

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Full Compliance with Nasdaq Listing Requirements

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced its receipt of notice from The Nasdaq Stock Market on Jan. 5, 2021, that VistaGen has regained compliance … Continue reading

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Publication Detailing Its Investigational Neuropharmaceuticals for Anxiety and Depression Disorders

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that VistaGen Vice President, Translational Medicine Dr. Louis Monti and VistaGen CNS Clinical and Regulatory Advisory Board Member … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment